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Abstract: 
Pancreas transplantation has gained clinical acceptance since its initial application more than 30 
years ago. A constellation of surgical, pharmacologic, and metabolic alterations occur with 
transplantation, particularly if pancreatic transplantation is performed in addition to renal 
transplantation in a uremic diabetic. Increasingly sophisticated studies have allowed analysis of 
the performance of the transplanted organ and have enhanced our basic understanding of 
insulin’s complex interplay in peripheral glucoregulatory processes. 
 
Article: 
Clinical experience with pancreas transplantation was not overwhelmingly successful during the 
late 1960s and early 1970s [1]. Over the next 20 years a period of constant reevaluation and 
reassessment of early clinical failures resulted in the development of animal models of 
transplantation. These models ultimately led to advances in surgical techniques and 
immunosuppression therapy and provided a better understanding of the impact of surgically 
induced alterations to the pancreas on carbohydrate metabolism. As pancreas transplantation 
enjoyed an increasing success rate and longer patient survival, posttransplant graft physiology 
and the metabolic response to the new insulin source became an interesting area of research. 
 
EARLY MODELS OF TRANSPLANTATION  
Surgical alterations of the pancreas that occur during transplantation include (1) reduction of the 
beta cell mass (by resection, immunologic loss, or preservation ischemic loss); (2) systemic 
venous drainage versus portal venous drainage of the pancreatic venous effluent; and (3) 
denervation. Surgical alterations per se should lead to an altered insulin source. What effect, if 
any, might this have on peripheral levels of insulin or insulin’s glucoregulatory properties? 
Would it ultimately affect the function of the transplanted pancreas? To address these questions 
and attempt to delineate the role of surgical alterations of the pancreas on longterm glucose 
homeostasis in transplanted patients, studies were performed using primarily dog or rat models. 
 
Reduction of Beta Cell Mass 
The complex interplay between insulin secretion and insulin action was suggested nearly 50 
years ago by Dragstedt et al.’s observation that the amount of insulin required to control glucos-
uria after partial pancreatectomy exceeded the amount needed after complete pancreatectomy 
[2]. Subsequently, it became evident that surgical models of partial pancreatectomy might result 
in alterations of alpha and beta cell ratios, which could explain earlier observations. Studies 
evaluating a dog model of 60% to 80% partial pancreatectomy showed that these animals have a 
reduced insulin response to the intravenous glucose tolerance test (IVGTT) and altered 
potassium values, indicating altered glucose metabolism [3]. It was suggested that 
pancreatectomy led to a postoperative state of hyperglycemia, which results in depleted beta cell 
insulin stores and reduced insulin responses to glucose and non-glucose stimulation [4]. Others 
suggested that resection might result in lowered peripheral levels of insulin, with concomitant 
enhanced peripheral sensitivity [5]. There was, however, no uniform agreement to the latter 
concept. 
 
Systemic Drainage 
The complete diversion of pancreatic venous flow from the portal to the systemic venous circuit 
would have particular anatomic relevance to transplantation and, perhaps, specific metabolic 
consequences. The importance of insulin’s major glucoregulatory properties and its relation to 
glucagon have been well studied. Cherrington et al. described 35% suppression of hepatic 
glucose output by insulin during somatostatin-suppressed glucagon deficiency [6]. This report 
and others have underscored the importance of the presence of insulin in the portal circulation to 
modulate these effects [7]. However, other reports have stated that peripheral rather than portal 
levels of insulin were more important for optimal glucose handling [8]. 
 
Despite the controversy about portal versus systemic release of insulin, few reports evaluated 
endogenous systemic venous insulin release. Florack et al. reported that basal amounts of insulin 
continue to exist in the portal vein after complete systemic diversion, and additionally, decreased 
peripheral insulin levels occur after systemic diversion of a reduced beta cell mass. They 
concluded that systemic drainage itself had little effect in dog models of transplantation [3]. 
 
Transplantation (Denervation) 
Pancreas transplantation combines the effects of anatomic reduction of the beta cell mass with 
systemic drainage and, additionally, denervation. Some reports suggest that vagotomy had no 
effect on insulin release after oral or intravenous glucose challenge [9]. The pancreas transplant 
model allows in vivo evaluation of denervation. Early studies of pancreatic autograft and 
allograft models suggested that fasting and stimulated insulin release was enhanced or at least 
that elevated peripheral levels of insulin were attributed to a combination of denervation and 
systemic venous drainage [10]. Other studies did not universally corroborate enhanced insulin 
release in the dog autotransplant model. Florack et al. showed lowered serum insulin levels in 
segmental pancreas transplants [3]. Munda et al. [11] reported normal fasting but enhanced 
arginine-stimulated insulin levels, and Cutfield et al. [12] reported fasting hyperinsulinemia with 
a lowered integrated insulin response to intravenous glucose stimulation. 
 
CLINICAL STUDIES OF PANCREAS TRANSPLANTATION 
By the early 1980s, largely through the diligence and persistence of Sollinger at the University of 
Wisconsin and Sutherland at the University of Minnesota, pancreas transplantation enjoyed 
acceptable success especially in a select group of type I diabetes patients with significant, 
progressive complications. The use of simultaneous renal transplantation in patients with 
predictably progressive diabetic nephropathy appeared to have the best patient and graft survival 
[13]. During this same period, as a result of earlier animal studies, there was increasing 
knowledge of the peripheral action of insulin and increased understanding of insulinotropic 
hormones, such as glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide 
(GLP), and the role of pancreatic polypeptide and somatostatin in the regulation of insulin 
release. This information allowed more sophisticated studies of pancreas transplantation. The 
standard IVGTT and oral glucose tolerance test (OGTT) were replaced by computer-controlled 
hyperglycemic or hyperinsulinemic challenges (―Clamp‖) that allowed a steady-state challenge 
to the pancreas allowing us to measure insulin release or to peripheral target organs allowing 
quantitative analysis of hepatic glucose production or peripheral glucose disappearance [14]. 
 
Initial Experience at the University of Virginia 
Clamp Studies. In 1990 initial studies employing the Andres hyperglycemic clamp on 11 
pancreas/kidney transplant recipients, 7 kidney transplant recipients, and 7 normal controls were 
completed [15]. Each patient underwent a 120 minute stable hyperglycemic clamp challenge, and 
multiple parameters of glucose homeostasis were measured including hormone levels and insulin 
action on hepatic glucose production and peripheral glucose disposal. The pancreas/renal 
transplant group had significantly elevated (fourfold) basal and glucose-stimulated insulin levels 
compared to the renal transplant and normal control groups (Fig. 1). 
 
 
 
This was mirrored in associated C-peptide and glucagon levels but was not appreciated in 
pancreatic polypeptide levels. We found that, despite marked systemic hyperinsulinemia in the 
pancreas/ kidney group, hepatic glucose production was normal in the basal and glucose-
stimulated states. We thought that these data showed that portal vein insulin was not essential for 
normal control of the hepatic glucose production and peripheral glucose disposal. 
 
Portal Drainage of Pancreas Allograft. Because of significant hyperinsulinemia and the 
possibility of long-term metabolic consequences and perhaps atherogenesis, a model of pancreas 
transplantation employing portal drained anatomy has been described [16]. The recipient splenic 
vein is anastomosed to the donor portal vein and in a fashion that would allow complete portal 
venous release of all transplant venous effluent. We studied three such portal vein drainage 
patients and compared them to 18 preoperative diabetic patients and 18 systemic drainage 
patients [17]. Employing an OGTT, we were intrigued that the peripheral glucose levels were 
identical in response to orally ingested glucose in the systemic and portal vein drainage groups. 
Hyperinsulinemia persisted in the portal vein drainage group, although it was significantly lower 
than that in the systemically drained group. These studies confirmed what was previously hinted 
at in previous studies; that is, varying endogenous levels of insulin after transplantation seemed 
to have little effect on glucose homeostasis in the periphery. Portal venous drainage resulted in 
partial normalization of peripheral plasma insulin levels. 
 
Longitudinal Analysis of Pancreas Transplantation. Our group proceeded on a longitudinal 
study of graft function after pancreas transplantation whereby the hyperglycemic clamps were 
repeated at 1-year intervals [18]. We were intrigued that the hyperinsulinemic response to the 
clamp persisted, although it was decreased approximately 30% from the previous year. We 
thought that the lower insulin concentrations in the follow-up studies were not attributable to the 
decreased clearance of insulin, as the rates of decline and disappearance of plasma insulin after 
determination of the glucose infusion between the two studies were similar. We also thought that 
causes could include an evolving reduction in viable beta cell number, a deficit in beta cell 
function, or increased peripheral insulin sensitivity. The data suggest a time-related decrease in 
insulin secretion, and this was confirmed by analysis of the C-peptide responses during the 
hyperglycemia. Follow-up studies measuring hepatic glucose output during the basal and 
hyperglycemic portions of the clamp demonstrated little difference from initial studies compared 
to repeat studies 1 year later. Measurement of peripheral glucose disappearance showed little 
difference from normal controls or changes over a 12-month period. 
 
PANCREAS TRANSPLANTATION AND GLUCOSE REGULATION 
Increasing success with the clinical application of pancreas transplantation in addition to 
improved clamp methodology have allowed more sophisticated analysis of posttransplant 
alterations in carbohydrate metabolism at many centers around the world. The literature has 
confirmed some of the earlier findings in the animal models and has provided further insight into 
the complex interplay of insulin’s glucoregulatory properties. 
 
Hyperinsulinemia and Altered Metabolism. The most apparent change in transplantation is that a 
new insulin source is supplying a different amount of insulin into a different circuit in the 
recipient (for those undergoing systemic drainage). Luzi et al. [19] evaluated glucose and free 
fatty acid metabolism in uremic diabetic patients after systemically drained pancreas 
transplantation with simultaneous renal transplantation. This group confirmed the previous 
findings of hyperinsulinemia and additionally reported that these patients had normal basal free 
fatty acid (FFA) turnover and that the new insulin source resulted in normal inhibition of FFA 
turnover and oxidation. Using the insulin clamp, however, the group showed that suppression of 
hepatic glucose production was defective in transplant patients compared to that in normal 
controls. 
 
Christiansen’s group also evaluated hyperinsulinemia on whole- body glucose metabolism. 
These authors reported that during acute hyperinsulinemia (―clamp‖) nonoxidative glucose 
metabolism was impaired in the pancreas transplant group compared to that in normal controls 
[20]. This finding was similar to that of Luzi et al. [19] and further identified that defective 
skeletal muscle glycogen synthetase activity could partially explain the defect. The report 
suggests that this defect could explain the resulting chronic peripheral hyperinsulinemia. 
 
Kendall et al. [21] addressed the important question of the effect of posttransplant 
hyperinsulinemia on counterregulatory processes. This group used graded hyperinsulinemia 
increases to establish graded hypoglycemia and evaluated epinephrine and nonepinephrine 
responses. The epinephrine response to maximal hypoglycemia was improved compared to that 
in type I diabetics; however, the pancreas transplant group response was still significantly lower 
than that in normal controls and a kidney transplant control group. Interestingly, cognitive 
recognition of hypoglycemic symptoms improved dramatically in this group and approached that 
of normal controls. 
 
The question of systemic versus portal delivery of insulin as a cause of hyperinsulinemia has led 
to altering techniques to avoid significantly increased insulin levels. Our group has attempted to 
do this, with improvement but not complete normalization of insulin values, as addressed earlier. 
More recently, Gaber’s group has reported preliminary data showing that, in response to oral 
glucose and nutrient solutions, basal and stimulated insulin levels may approach normal values 
for portal-drained whole pancreas transplantation [22]. 
 
Other intriguing explanations for significant posttransplant hyperinsulinemia were suggested by 
two groups. Luzi et al. studied insulin-induced hypoglycemia in pancreas transplant patients and 
hypothesized that feedback inhibition of insulin is normally under neural control [23]. After 
transplantation (with denervation) insulin inhibition is only partially restored, most likely due to 
catecholamine release. The blunted feedback inhibition might well cause, or partially explain, the 
peripheral hyperinsulinemia. 
 
Altered Insulin Secretion and Sensitivity. The use of high-dose immunosuppression including 
steroids and cyclosporine may well affect insulin sensitivity. Additionally, the reduced secretory 
capability of the transplanted B (beta) cell mass has been studied. Teuscher et al. reported that 
the acute maximal insulin response to arginine stimulation was significantly reduced in whole 
gland cadaveric transplant patients and even more so in segmental gland transplant at the 
University of Minnesota, one of the few centers that employs the latter procedure [24]. 
 
Insulin secretion and peripheral sensitivity were studied extensively by Christiansen et al. [25]. 
They compared two sets of patients who had had cadaveric segmental pancreas transplants 
combined with renal grafts: one with ―normal glucose tolerance according to WHO criteria‖ and 
four other patients with ―abnormal‖ glucose tolerance. These two groups were compared to 
kidney transplant recipients and normal controls. This study demonstrates a number of 
interesting points. First, immunosuppression results in increased insulin secretion in response to 
an oral glucose load, raising the question of decreased peripheral sensitivity. Second, peripheral 
glucose disappearance is comparable for normal kidney recipients and ―normal‖ functioning 
pancreatic grafts. The second group of pancreatic grafts had parameters of failure that suggest 
impaired first-wave insulin secretion, reduced B cell responsiveness, and impaired nonoxidative 
glucose metabolism. This latter group of patients also had impaired early inhibition of glucagon 
secretion. 
 
Cottrell addressed the issue of insulin sensitivity after pancreas transplantation and how it might 
change over time [26]. That study addressed the fact that immunosuppressive drug doses are 
often significantly decreased after the first 12 months. It evaluated whole pancreas and kidney 
recipients sequentially from immediately after surgery (3–6 months) to 48 months. Stable 
euglycemia was documented over the whole period. Peripheral sensitivity was diminished during 
the early phase, for which compensatory hyperinsulinemia and enhanced peripheral glucose 
disappearance occurred. At 12 to 24 months insulin sensitivity appeared to improve, although 
residual hyperinsulinemia persisted. Cottrell thought that the decreasing insulin response to 
glucose change over this time was not due to diminished B cell capacity but to changing (and 
improving) peripheral sensitivity most likely affected by decreased immunosuppressive drug 
therapy. 
 
Rooney and Robertson investigated insulin sensitivity in more depth by evaluating insulin action 
on the liver after pancreas transplantation [27]. This group evaluated 10 pancreas transplant 
recipients (two solitary and eight simultaneous renal transplants) and compared them to normal 
controls and renal transplant patients using a hyperinsulinemic clamp study. The clamp protocol 
included an additional 90 minutes of glucagon stimulation after a 120 minute euglycemic 
hyperinsulinemic challenge. Several intriguing findings were reported. First, exogenous insulin 
sup pressed hepatic glucose production (HGP) in all three groups, yet HGP transplantation 
should allow significant improvements in knowledge about carbohydrate and lipid metabolism 
(Fig. 2). 
 
 
 
An intrinsic alteration in insulin action in the liver and in the periphery appears to be taking place 
after pancreas transplantation. Whether placing grafts in the portal circulation can ameliorate the 
effect must be studied. 
 
AREAS OF FUTURE RESEARCH 
Posttransplant Improvement in Exercise Tolerance 
Exercise in normal, healthy individuals results in a decrease in insulin and an increase in 
glucagon so normal glucose levels can be maintained. Catecholamines work in a ―feed-forward‖ 
system to increase hepatic glucose production by suppressing insulin action, and this suppression 
is proportional to the intensity of the exercise. Denervation of the pancreas due to transplantation 
results in a loss of normal neural input to the pancreas islets during exercise and may result in a 
decline of blood glucose levels during exercise [28]. Alternatively, it has been hypothesized that 
during stress abnormal sensitivity to circulating catecholamine levels could result in 
hyperglycemia due to impaired insulin secretion [29]. The only study investigating the effects of 
exercise on glucose regulation in pancreas transplant patients was completed by Redmond et al. 
[28]. Glucose, insulin, and glucagon concentrations were monitored during 1 hour of exercise 
(40% of each individual’s VO2 peak) in normal, healthy individuals and systemically drained 
pancreas transplant patients matched for age, height, weight, and exercise training status. 
Glucose levels declined after the onset of exercise in both groups. The insulin and C-peptide 
levels decreased significantly and glucagon levels rose significantly in the normal subjects. 
Similar trends were observed in the pancreas transplant patients, but the changes were not 
significant and were somewhat delayed. This delay, or ―lag,‖ in the response of the glucose 
homeostasis system with exercise should be expected in systemically drained pancreas transplant 
patients, as normal neural connections to the pancreas are missing and blood from the pancreas 
misses the ―first pass‖ through the liver. This group concluded that although subtle alterations in 
insulin and glucagon secretion may occur during exercise they do not result in clinically 
significant changes in blood glucose. These data indicate that the lack of neural innervation in 
pancreas transplant patients does not affect their ability to maintain normal blood glucose levels 
during 1 hour of exercise at 40% VO2 peak. These subtle, insignificant changes may be more 
profound during higher intensity exercise when stress to the system is greater, and the delay in 
the response may have greater effects on overall glucose homeostasis. Alternatively, it can be 
postulated that the catecholamine ―feed-forward‖ system is so efficient at stimulating hepatic 
glucose production the changes in blood flow and lack of neural input are of minimal 
consequences regardless of the intensity of exercise. 
 
Additionally, the time since transplantation for the pancreas transplant patients in the Redmond 
study was relatively short (less than 2 years), and it is difficult to predict the outcome of this 
study in a group of pancreas transplant patients who had received an allograft more than 5 years 
previously. The effects of long-term hyperinsulinemia in pancreas transplant patients is not 
known, and its effect on exercise tolerance in this group has not been studied. Clearly, more 
studies of exercise tolerance in pancreas transplant patients are warranted, because this 
information is crucial as the role of long-term hyperinsulinemia in pancreas transplant patients is 
more completely understood. 
 
Posttransplant Hyperinsulinemia, Alterations in Lipid Metabolism, and Risk of Coronary Heart Disease 
The clustering of certain physiologic disorders (e.g., hypertension, obesity, dyslipidemia, 
hyperinsulinemia) in a single individual (the deadly quartet, the metabolic syndrome, syndrome 
X) and the increased risk for coronary heart disease (CHD) has been described. In type II 
diabetics hyperinsulinemia has been thought to be due to peripheral resistance; and in these 
individuals altered lipid metabolism, hypertension, and enhanced coronary and peripheral vessel 
atherosclerosis occurs [30]. It has been suggested that hyperinsulinemia plays a central role in 
the development of these physiologic disorders, and a strong argument has been made that 
elevations in insulin concentration precede the development of numerous metabolic disorders 
[31]. Intriguingly, however, we have found little to suggest the consequences of dyslipidemia or 
hypertension in posttransplant patients with surgically created hyperinsulinemia in our studies or 
in others. Scattered reports have attempted to evaluate altered lipid levels and have shown 
normal or nearly normal lipid and lipoprotein levels. Peripheral hyperinsulinemia up-regulates 
lipoprotein lipase (LPL) activity, especially in fatty tissues, leading to low postprandial lipemia 
and some favorable changes in lipid profiles [32]. However, studies investigating the influence 
of hyperinsulinemia on lipoproteins after pancreas transplantation have observed unfavorable 
changes in the surface composition of plasma lipoproteins, but the clinical importance remains 
questionable because it is accompanied by lower postprandial lipemia [33]. Additionally, the 
specific up- regulation of LPL in the abdominal visceral area of pancreas transplant patients and 
its effects on intraabdominal visceral fat accumulation in these individuals is currently unknown. 
Of critical importance is the fact that hyperinsulinemia in the ―normal‖ scenario rarely occurs 
without other metabolic aberrations, such as dyslipidemia, obesity, or hypertension. In pancreas 
transplant patients it is rare to find clustering of these metabolic problems, as is commonly found 
in the ―metabolic syndrome‖ or ―syndrome X.‖ Although hyperinsulinemia has been shown to 
precede other metabolic aberrations in nontransplant patients [30], it is impossible to know the 
effect of hyperinsulinemia when it is isolated, specifically without the effect of obesity. 
Therefore despite post- transplantation hyperinsulinemia, the ―metabolic syndrome,‖ for 
whatever reason, does not seem to be occurring—yet few of these studies is longer than 2 years 
and no in-depth longitudinal studies can be found. On the other hand, there is extensive literature 
about the effects of chronic hyperinsulinemia in other clinical circumstances, such as type II 
diabetes. 
 
The alterations in metabolism as a result of hyperinsulinemia are predictable and severe, leading 
to the question of the possible long-term effects of this state with pancreas transplantation. 
Improvement in transplantation techniques and immunosuppressive therapy have increased the 
long-term survival of pancreas transplant patients. Currently, two studies have investigated long-
term survival and cause of death in pancreas transplant patients [34, 35]. 
 
Wilson et al. [34] observed a decreased graft survival rate in obese pancreas/kidney recipients 
with a body mass index of less than 27. Despite the decreased graft survival rate for both the 
kidney and pancreas in the obese group, the incidence of hypertension or lipid abnormalities did 
not differ in the two groups. Graft function and immunosuppressive exposure were similar; and 
although posttransplant complications tended to be more common in obese patients, the 
difference was not statistically significant. Interestingly, the most common cause of death was 
cardiac complications, and the 5-year patient survival rate had a downward trend in the obese 
group (68% vs. 85%). Although this was not statistically significant, a difference of 17% in the 
survival rate is large and should be noted. 
 
More recently, Sollinger et al. [35] reported their experience with 500 simultaneous 
pancreas/kidney transplants. The data show that this is a highly successful transplant procedure 
with 76.3% patient survival after 10 years. Similar to the Wilson et al. study [34], the most 
common cause of death was cardiac complications (38%). In this group, 12 of 20 patients died of 
myocardial infarction. Mortality statistics from these two studies clearly indicate that coronary 
complications are likely to occur in posttransplant patients and the possible role of 
hyperinsulinemia for increased risk of coronary heart disease (CHD) should not be overlooked. 
 
Intraabdominal Visceral Fat 
As early as 1963, Randle et al. [36] proposed that increased FFA levels were associated with 
preferential FFA oxidation, which then interfered with other processes such as insulin action and 
glucose oxidation and storage. The authors elaborated on this glucose-fatty acid concept and 
suggested that elevated FFA levels would have a mechanistic role in the development of certain 
metabolic disorders, including type II diabetes. Perhaps more importantly, it has been shown that 
the regional distribution of body fat is related to lipolytic activity [37]. Intraabdominal visceral 
fat shows the highest lipolytic activity, whereas peripheral fat depots such as gluteofemoral 
adipose tissue has blunted lipolytic activity. This has led to the suggestion that these regional 
differences in lipolytic activity of fat stores are related to metabolic complications, with 
increased levels of intraabdominal visceral fat being related to the highest risk of metabolic 
complications [38]. Portal adipose tissue (omental and mesenteric) has been shown to be highly 
sensitive for mobilization of FFAs with increased a-adrenergic receptors and reduced a-
adrenergic inhibition [38]. Therefore in individuals with elevated levels of intraabdominal 
visceral fat there is a greater flux of FFAs to the liver through the portal circulation [38]. 
 
It has been shown that increased intraabdominal visceral fat (AVF) results in increased risk of 
CHD in the normal population Therefore it is highly possible that hyperinsulinemia in pancreas 
transplant patients may lead to increased risk of CHD not by affecting lipid levels directly but, 
rather, by increasing the accumulation of AVF. Unfortunately, no studies investigating AVF 
levels have been completed in pancreas transplant patients. It would be interesting to see how 
AVF levels in these patients compare to those in normal healthy individuals, obese individuals, 
and CHD patients. Although AVF levels in pancreas transplant patients may be similar or even 
lower than those observed in these higher risk groups, it is also important to consider the change 
in AVF that occurs from before transplantation to afterward. In the pancreas transplant patient, 
small amounts of AVF may lead to an increased chance of metabolic change and possibly CHD, 
as the effect of rerouting the blood flow systemically and the effect of altering organs and fat as a 
result of transplantation are unknown. Considering the link between increased AVF and the 
increased risk of CHD in the normal population, it would be interesting to assess the survival rate 
based on AVF in a group of pancreas transplant patients. The observations concerning 
hyperinsulinemia, AVF, and CHD post interesting and paramount questions about the influence 
of systemic versus portal delivery of insulin. 
 
Peripheral Glucose Transporters 
In peripheral tissues, especially skeletal muscle cells, glucose is not freely permeable across the 
cell membrane. It appears that specific protein transporters effect passive transport down a 
concentration gradient. Several transporter proteins encoded at different gene sites have been 
recently identified and characterized [40]. Under normal circumstances, adipose and skeletal 
muscle cells respond to increasing levels of insulin by increased glucose transport via 
translocation of the transporter protein across the cell membrane. In skeletal muscle the GLUT-4 
transporter protein is the most important physiologically [41]. 
 
Recently, skeletal muscle transporter activity has been studied in several disease states. 
Interestingly, consistent evidence fails to find altered levels of the transporter protein in insulin-
resistant states, either with decreased insulin secretion in type I diabetes or hyperinsulinemic 
states such as type II diabetes [42]. Because of the failure to find altered levels of the transporter 
protein in insulin-resistant states, including obesity, it has been hypothesized that the pathology 
resided in altered function of the transporter or perhaps initiation of the insulin receptor–
transporter protein interaction. We were therefore intrigued to find a significant (45%) reduction 
in GLUT 4 protein in skeletal muscle (vastus lateralis) of pancreas/renal transplants in our 
studies of pancreas transplant patients [18]. These data represented one of the first reports and 
possibly the only time that significant down-regulation of a peripheral glucose transporter protein 
has been shown as a possible explanation for what appears to be ―normal‖ glycemic control in 
the face of the hyperinsulinemia after pancreas transplantation. Clearly, longitudinal studies of 
changes in GLUT 4 protein content in pancreas transplant patients are necessary. 
 
It is well established that pancreas transplant patients have peripheral hyperinsulinemia, 
regardless of whether the allograft is systemically or portally drained. Both short-term (7 days) 
[43] and long-term (14 weeks) [44] exercise training have been shown to increase muscle GLUT 
4 protein content by two- to threefold. One would expect that exercise training of pancreas 
transplant patients after surgery would also result in increased GLUT 4 protein content and 
improved insulin sensitivity. We do not know of any exercise training studies in pancreas 
transplant patients that have systematically addressed the issue of changes in GLUT 4 protein 
content in skeletal muscle. Data from Redmond et al. [28] tend to indicate that although the 
pancreas transplant patients have increased insulin levels, they maintain near-normal glucose 
levels during exercise. It is possible that because increases in GLUT 4 transporter activity can be 
achieved through ―insulin- independent‖ mechanisms during exercise (stimulated by contraction 
and Ca
2+
) the pancreas transplant patients have developed a peripheral adaptation in the GLUT 4 
transporter that is independent of insulin levels and functions to maintain normal levels of the 
GLUT 4 transporter despite hyperinsulinemia. Studies investigating exercise training-induced 
changes in GLUT 4 protein content in pancreas transplant patients are necessary to understand 
the role they play in maintaining glucose homeostasis during physical activity in the pancreas 
transplant patients. 
 
Pulsatile Insulin Release 
There has been increasing evidence that the pulsatile release of various hormones, especially 
those from the hypothalamus, has much to do with their peripheral efficacy. There is suggestive 
evidence that altered patterns of pulsatile insulin release may be an early marker for type II 
diabetes [45]. The extent to which and the type of defects in the wave-like pattern of insulin 
release might contribute to frank diabetes or minimal alterations in peripheral glucose 
metabolism is unknown. Increasing knowledge is describing such defects, however. Recent 
studies in dogs have studied the pulsatile and nonpulsatile insulin appearance in the portal system 
and systemically. Porksen’s group has used methods to quantitate the pulsatile parameters of 
insulin’s actions and has calculated that as much as two-thirds of the mass of insulin secreted is 
in pulsatile form [46]. They hypothesized that alterations in waveform delivery could affect 
peripheral efficiency. Studies evaluating altered pulsatility in transplant patients have begun to 
emerge, testing the hypothesis that autonomic interruption may affect insulin action by altering 
the patterns of release. Sonnenberg et al. evaluated six patients who had received simultaneous 
whole pancreas and kidney grafts during basal and enteric stimulated time periods [47]. The high 
frequency waveform in patients with transplants was identical to that in normal controls; a low 
frequency waveform was maintained, but the amplitude was diminished. Further studies with the 
development of pulsatility analysis should allow sophisticated analysis of the importance of the 
characteristics of insulin release, which may be more important than peripheral levels or the 
mass of insulin secreted. 
 
CONCLUSIONS 
Robertson et al. correctly pointed out that pancreas transplantation is ―here to stay‖ [1]. In 
addition to supplying a new endogenous source of insulin in cases of complicated diabetes, the 
transplant results in altered glucose metabolism. Whether serious long-term consequences of 
such alteration will affect the overall success of transplantation is unknown. Careful and 
increasingly sophisticated studies of patients with transplants and animal models evaluating the 
surgical alterations of pancreas transplantations should allow significant improvements in our 
knowledge of carbohydrate and lipid metabolism. 
 
RÉSUMÉ 
La transplantation du pancréas a acquis une place dans la pratique clinique depuis son début il y 
a 30 ans. On assiste à une constellation de modifications chirurgicales, pharmacologiques et 
métaboliques en rapport avec la transplantation, particulièrement si elle est pratiquée en même 
temps que la transplantation rénale chez un diabétique urémique. Il existe de plus en plus 
d’études sophistiquèes pour permettre une analyse de la performance des organes transplantés, 
ainsi qu’une meilleure compréhensin du rôle complexe de l’insuline dans le processus de la 
régulation glucidique périphèrique. 
 
RESUMEN 
El trasplante de páncreas ha ganado aceptación clínica desde su aplicación inicial hace más de 30 
aiios. Luego del trasplante sobreviene una constelación de alteraciones guirúrgicas, 
farmacológicas y metabólicas, especialmente si el trasplante de páncreas se hace adicional a un 
trasplante renal en pacientes con uremia diabética. Nuevos y sofisticados estudios han permitido 
el análisis del comportamiento del órgano trasplantado, e incrementado el conocimiento básico 
de la compleja interrelación de la insulina en los procesos glucoregulatorios periféricos. 
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